Accelerate Diagnostics, Inc. Announces New Accelerate Pheno System Multi-Center Study Published in Clinical Infectious Diseases
November 22, 2021 at 07:00 am EST
Share
Accelerate Diagnostics, Inc. announced the publication of its Improving Outcomes and Antibiotic Stewardship (IOAS) Study in the journal Clinical Infectious Diseases. The multi-center, real-world study compared data before and after implementation of the Accelerate Pheno system across several hospitals to determine its impact on the treatment of patients with bloodstream infections. The data showed statistically significant reductions in time to optimal antimicrobial therapy, modification, and de-escalations associated with widespread patient benefits. The study included endpoints for microbiology test turnaround time, antimicrobial use, hospital length of stay, and 30-day mortality. The data showed that using Accelerate Pheno system reduced time to optimal antimicrobial therapy by 17.2 hours (median, IQR), time to first antimicrobial modification by 10.3 hours (median, IQR), and antimicrobial de-escalation time by 8.8 hours (median, IQR). The value of early antimicrobial optimization is likely associated with widespread patient and societal benefits such as limiting the emergence of antimicrobial resistance and reducing harm from unnecessary antimicrobial exposures. In addition, there was a 1-day reduction in hospital length of stay for patients with Gram-negative bloodstream infections, which are increasingly resistant to antibiotics, in the post-Accelerate Pheno implementation group. Furthermore, within the group of patients who were initially on ineffective antimicrobial therapy, time to effective therapy was reduced by 6.6 hours (median, IQR) and there was a clinically significant reduction of 6.4% in the 30-day mortality rate in the post-Accelerate Pheno implementation group. These findings highlight that the effects of early identification and antimicrobial susceptibility testing for patients with bloodstream infections were substantial and widespread in this sizable multi-center study.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.